Postoperative radiotherapy in intermediate and high-risk Stage I endometrial cancer: analysis of prognostic factors and survival

Purpose: Patients with Stage IA Grade (G) III, Stage IB GII-III and Stage IC GI-II-III endometrial cancer who received postoperative adjuvant radiotherapy were evaluated in terms of local control, disease-free and overall survival rates and prognostic factors. Materials and Methods: Four hundred and three patients with Stage I endometrial cancer treated with radiotherapy from January 1990 to December 2003 at Ege University Faculty of Medicine Department of Radiation Oncology were reviewed retrospectively. According to our radiotherapy protocol patients with Stage IB G2 disease (149 patients) received only external radiotherapy and the remaining (254 patients) received both external radiotherapy and intracavitary brachytherapy. Results: Median age of the patients was 58 (range: 37-83). Nine patients (2.2%) had Stage IA, 196 (48.6%) had Stage IB and 198 (49.1%) had Stage IC disease. Histologic grade was 1 in 52 (12.9%) patients, 2 in 268 (66.5%) patients and 3 in 83 (20.6%) patients. Seventy-one (17.7%) patients had lymphovascular space invasion. Five-year locoregional relapse-free, distant-free, disease-free survival (DFS) and overall survival (OS) were 98.2%, 92.8%, 91.8% and 87.7%, respectively. In multivariate analysis, myometrial invasion and lymphovascular invasion were predictive factors for DFS and for OS prognostic factors were histologic type, myometrial invasion, and histologic grade. During radiotherapy 47.9% of the patients developed acute morbidity and 26.3% developed late morbidity, vaginal stenosis being the most frequent late morbidity. Conclusion: Postoperative adjuvant radiotherapy provides high locoregional control rates with acceptable toxicity in selected patients with Stage I endometrial carcinoma.

Intermediate and high risk stage I endometrial cancer; Radiotherapy; Prognostic factors

[1] Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C. et al.: “Cancer Statistics, 2006”. Cancer J. Clin., 2006, 56, 106.

[2] Macdonald O.K., Sause W.T., Lee R.J., Lee C.M., Dodson M.K., Zempolich K. et al.: “Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: A multi-intuitional analysis of 608 women”. Gynecol. Oncol., 2006, 103, 661.

[3] Eltabbakh G.H., Pıver S.M., Hempling R.E., Shin K.H.: “Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymphnode sampling: report of a prospective trial”. Int. J. Radiat. Oncol. Biol. Phys., 1997, 38, 373

[4] Touboul E., Belkacemi Y., Buffat L., Deniaud-Alexandre E., Lefranc J.P., Lhuillier P. et al.: “Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients”. Int. J. Radiat. Oncol. Biol. Phys., 2001, 50, 81.

[5] Naumann R.W., Coleman R.L.: “The use of adjuvant radiation therapy in early endometrial cancer by members of the society of gynecologic oncologists in 2005”. Gynecol. Oncol., 2007, 105, 7.

[6] Lukka H., Chambers A., Fyles A., Thephamongkhol K.,Fung-Kee- Fung M., Elit L. et al.: “Adjuvant radiotherapy in women with stage I endometrial cancer: A systematic review”. Gynecol. Oncol., 2006, 102, 361.

[7] Creutzberg C.L., van Putten W.L.J., Koper P.C., Lybeert M.L., Jobsen J.J., Wárlám-Rodenhuis C.C. et al.: “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial”. The Lancet, 2000, 355, 1404.

[8] Creutzberg C.L., van Putten W.L., Warlam-Rodenhuis C.C., van den Bergh A.C., de Winter K.A., Koper P.C. et al.: “Outcome of high-risk stage IC, Grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial”. J. Clin. Oncol., 2004, 22, 1234.

[9] Grigsby W.P., Perez C.A., Kuten A., Simpson J.R., Garcia D.M., Camel H.M. et al.: “Clinical stage I endometrial cancer: Results of adjuvant irradiation and patterns of failure”. Int. J. Radiat. Oncol. Biol. Phys., 1992, 21, 379.

[10] Aalders J., Abeler V., Kolstad P., Onsrud M.: “Postoperative external irradiation and prognosis parameters in stage I endometrial carcinoma: clinical and histopathogenic study of 540 patients”. Obstet. Gynecol., 1980, 56, 419.

[11] Hendrickson M., Ross J., Eifel P.J., Cox R.S., Martinez A., Kempson R.: “Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Pathology review and analysis of prognostic variables”. Gynecol. Oncol., 1982, 13, 373.

[12] Christopherson W.M., Connely P.J., Alberhasky R.C.: “ Carcinoma of the endometrium: an analysis of prognosticators in patients with favorable subtypes and stage I disease”. Cancer, 1983, 51, 1705.

[13] Hanson M.D., Van Nagell J.R., Powell D.E., Donaldson E.S., Gallion H., Merhige M. et al.: “The prognostic significance of lymphovascular space invasion in stage I endometrial cancer”. Cancer, 1985, 55, 1753.

[14] Nori D., Hilaris B.S., Tome M., Lewis J.L. Jr., Birnbaum S., Fuks Z.: “Combined surgery and radiation in endometrial carcinoma: an analysis of prognostic factors”. Int. J. Radiat. Oncol. Biol. Phys., 1987, 13, 489.

[15] Greeven K.M., Lanciano R.M., Herbert S.H., Hogan P.E.: “Analysis of complications in patients with endometrial carcinoma receiving adjuvant irradiation”. Int. J. Radiat. Oncol. Biol. Phys., 1991, 21, 919.

[16] Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M. et al.: “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2004, 92, 744.

[17] Ambros R.A., Kurman R.J.: “Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus”. Cancer, 1992, 69, 1424.

[18] Glassburn J.R., Brady L.W., Grigsby P.W.: “Endometrium”. In: Perez C.A., Brady L.W., Halperin E.C., Schmidt-Ulrich R.K.(eds.). Principles and Practice of Radiation Oncology. 4th edition, Philadelphia, Lippincott Williams & Wilkins, 2004, 1916.

[19] Stokes S., Bedwinek J., Kao M.S., Camel H.M., Perez C.A.: “Treatment of stage I adenocarcinoma of the endometrium by hysterectomy and irradiation: A retrospective analysis of 304 patients”. Int. J. Radiat. Oncol. Biol. Phys., 1986, 12, 339.

[20] Pearcey R.G., Petereit D.G.: “Postoperative high dose rate brachytherapy in patients with low to intermediate risk endometrial cancer”. Radiother. Oncol., 2000, 56, 17.

[21] Goff B.A., Rice L.W.: “Assessment of depth of myometrial invasion in endometrial adenocarcinoma”. Gynecol. Oncol., 1990, 38, 46.

[22] MacLeod C., Fowler A., Duval P., D’Costa I., Dalrymple C., Firth I. et al.: “High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer”. Int. J. Radiat. Oncology Biol. Phys., 1998, 42, 1033.

[23] Belinson J.L., Lee K.R., Badger G.J., Pretorius R.G., Jarrell M.A.: “Clinical stage I adenocarcinoma of the endometrium-analysis of recurrences and potential benefits of staging lymphadenectomy”. Gynecol. Oncol., 1992, 44, 17.

[24] Rush S., Gal D., Potters L., Bosworth J., Lovecchio J.: “Pelvic control following external beam radiation for surgical stage I endometrial adenocarcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 33, 851.

[25] FIGO Stages, 1988 Revision (Announcement). Gynecol. Oncol., 1989, 35, 125.

[26] Perez C.A., Brady L.W.: “Quantification of treatment toxicity”. In: Perez C.A., Brady L.W. (eds.). Principles and Practice of Radiation Oncology Philadelphia: JB Lippincott, 1992, 51.

[27] Chassagne D., Sismondi P., Horiot J.C., Sinistrero G., Bey P., Zola P. et al.: “A glossary for reporting complications of treatment in gynecological cancers”. Radiother. Oncol., 1993, 26, 195.

[28] Fyles A., Keane T.J., Barton M., Simm J.: “The effect of treatment duration in the local control of cervix cancer”. Radiother. Oncol., 2000, 57, 13.

[29] Fowler J.F., Lindstrom M.J.: “Loss of control with prolongation in radiotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 1992, 23, 457.

[30] Fossa B.J., Badzıo A., Jassem J.: “Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure”. Int. J. Gynecol. Cancer, 1999, 9, 285.

[31] Ahmad N.R., Lacianı R.M., Corn B.W., Schulthesis T.: “Postoperative radiation therapy for surgically staged endometrium cancer: impact of time factors (overall treatment time and surgery-to-radiation interval) on outcome”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 33, 837.

[32] Anderson B., Connor J.P., Andrews J.I., Davis C.S., Buller R.E., Sorosky J.I. et al.: “Obesity and prognosis and endometrial cancer”. Am. J. Obstet. Gynecol., 1996, 174, 1171.

[33] Everett E., Tamimi H., Greer B., Swisher E., Paley P., Mandel L. et al.: “The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer”. Gynecol. Oncol., 2003, 90, 150.

[34] Temkin S.M., Pezzullo J.C., Hellmann M., Lee Y.C., Abulafia O.: “Is body mass index an independent risk factor of survival among patients with endometrial cancer?”. Am. J. Clin. Oncol., 2007, 30, 8.

[35] Gates E.J., Hirschfield L., Matthews R.P., Yap O.W.: “Body mass index as a prognostic factor in endometriod adenocarcinoma of the endometrium”. J. Natl. Med. Assoc., 2006, 98, 1814.

[36] Kalogiannidis I., Lambrechts S., Amant F., Neven P., Van Limbergen E., Vergote I.: “Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: an analysis of 208 patients”. Int. J. Gynecol. Cancer, 2006, 16, 1885.

[37] Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Wárlám-Rodenhuis C.C. et al.: “The morbidity of treatment for patients with stage I endometrial cancer results from a randomized trial”. Int. J. Radiat. Oncol. Biol. Phys., 2001, 51, 1246.

[38] Sorbe B.G., Smeds A.C.: “Post-operative vaginal irradiation with high-dose rate afterloading technique in endometrial carcinoma stage I”. Int. J. Radiat. Oncol. Biol. Phys., 1990, 18, 305.

[39] Yalman D., Arıcan A., Ozsaran Z., Celik O.K.,Yurut V., Esassolak M. et al.: “Evaluation of morbidity after external radiotherapy and intracavitary brachytherapy in 771 patients with carcinoma of the uterine cervix or endometrium”. Eur. J. Gynaecol. Oncol., 2002, 23, 58.

[40] Bruner D.W., Lanciano R., Keegan M., Corn B., Martin E., Hanks G.E.: “Vaginal stenosis and sexual functioning following intracavity radiation for the treatment of cervical and endometrial carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 1993, 27, 825.